Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma

Frontiers in Oncology

Karda Cavanagh¹  Michelle S. Goh²  Luke McLean³  Rodney J. Hicks⁴  Angela Webb⁵  Danny Rischin⁶  Annette M. Lim⁶ 

[1] Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;Department of Dermatology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;Department of Plastic Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, VIC, Australia;

关键词: immunotherapy;    PD-1 inhibition;    pseudoprogression;    cutaneous squamous carcinoma;    second primary tumors (SPTs);   

DOI  :  10.3389/fonc.2021.656611

来源: DOAJ

【 摘 要 】

Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blockade. We highlight treatment issues distinct to the management of the disease including expansion of the traditional concept of pseudoprogression and describe delayed responses after immune-specific response criteria confirmed progressive disease with and without clinical deterioration. We term this phenomenon “delayed response after confirmed progression (DR)”. We also discuss the common development of second primary tumors, heterogeneous disease responses, and expanding clinical boundaries for immunotherapy use.

【 授权许可】

Unknown